The World Health Organization states pharmaceuticals represented a US $300 billion-a-year market globally as of 2015. The global pharmaceutical market is expected to surpass the US $400 billion by 2018, with the ten largest pharmaceutical companies altogether commanding about a third of the market. Companies in the pharmaceutical industry are symbolized by their sizeable expenditure on Research and Development and marketing initiatives in a bid to collect more revenue. The development of biopharmaceuticals serves a breakthrough for the industry and personalized therapies carry extremely large promise in the near future. Although mature markets continue to account for over half of all global revenue of the pharmaceutical industry, both large and alcove pharmaceutical companies are now waking up to the profitable potential that lies in growth markets.
The healthcare industry deals with the storage, exchange and management of healthcare records between laboratories, insurance agencies, hospitals, patients, and government bodies. The healthcare industry has seen aggressive growth over the last few years. New advances in the information technology domain, connected with the changing demands of patients and healthcare institutions, are combining to shape the future of the global healthcare information technology industry. Many countries are already taking the initiative in implementing extensive Electronic Health Records (EHRs) and as this trend spreads to more countries, several new areas will continue to emerge in the healthcare industry.
Trisenox is a chemotherapy drug and is also called Trisenox or ATO. It is a treatment for a type of acute myeloid leukaemia called acute promyelocytic leukaemia (APL).ﾠ LPI (LP Information)' newest research report, the ﾓTrisenox Industry Forecastﾔ looks at past sales and reviews total world Tr [...]
READ MOREVYXEOSﾠis a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, LPI (LP Information)' newest research report, the ﾓVyxeos Industry Forecastﾔ looks at past sales and reviews total world Vyxeos sales in 2022, providing a comprehensive analysis by regi [...]
READ MOREVYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, LPI (LP Information)' newest research report, the ﾓCytarabine and Daunorubicin Industry Forecastﾔ looks at past sales and reviews total world Cytarabine and Daunorubicin sales in 2022, pr [...]
READ MOREVYXEOSﾠis a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, LPI (LP Information)' newest research report, the ﾓCytarabine and Daunorubicin Drugs Industry Forecastﾔ looks at past sales and reviews total world Cytarabine and Daunorubicin Drugs sal [...]
READ MOREIvosidenibﾠis anﾠexperimental drugﾠfor treatment of cancer. It is aﾠsmall molecule inhibitorﾠofﾠIDH1, which is mutated in several forms of cancer. LPI (LP Information)' newest research report, the ﾓIvosidenib Drugs Industry Forecastﾔ looks at past sales and reviews total world Ivosid [...]
READ MORETibsovoﾠis anﾠexperimental drugﾠfor treatment of cancer. It is aﾠsmall molecule inhibitorﾠofﾠIDH1, which is mutated in several forms of cancer. LPI (LP Information)' newest research report, the ﾓTibsovo Industry Forecastﾔ looks at past sales and reviews total world Tibsovo sales in 2 [...]
READ MOREMidostaurin is a multi-targetedﾠprotein kinase inhibitorﾠthat has been investigated for the treatment ofﾠacute myeloid leukemiaﾠ(AML),ﾠmyelodysplastic syndromeﾠ(MDS) and advancedﾠsystemic mastocytosis. LPI (LP Information)' newest research report, the ﾓMidostaurin Industry Forecast� [...]
READ MOREMidostaurin is a multi-targetedﾠprotein kinase inhibitorﾠthat has been investigated for the treatment ofﾠacute myeloid leukemiaﾠ(AML),ﾠmyelodysplastic syndromeﾠ(MDS) and advancedﾠsystemic mastocytosis. LPI (LP Information)' newest research report, the ﾓMidostaurin Drugs Industry Fore [...]
READ MOREIvosidenibﾠis anﾠexperimental drugﾠfor treatment of cancer. It is aﾠsmall molecule inhibitorﾠofﾠIDH1, which is mutated in several forms of cancer. LPI (LP Information)' newest research report, the ﾓIvosidenib Industry Forecastﾔ looks at past sales and reviews total world Ivosidenib s [...]
READ MOREGemtuzumab ozogamicinﾠis a drug-linkedﾠmonoclonal antibodyﾠ(anﾠantibody-drug conjugate) that was used to treatﾠacute myeloid leukemiaﾠfrom 2000 to 2010. LPI (LP Information)' newest research report, the ﾓGemtuzumab Ozogamicin Drugs Industry Forecastﾔ looks at past sales and reviews t [...]
READ MORE
Pvt. Ltd.
